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ABSTRACT 
We have  shown previously that the  ~adrenergic agonist  isoproterenol (2  /zM) 
and the  phosphodiesterase  inhibitor isobutylmethylxanthine (1  mM)  produce  a 
much  greater  increase  in  cyclic  AMP  in  human  leukocytes  that  have  been 
pretreated with colchicine (or with other agents that affect microtubule assembly) 
than in control leukocytes. The effects of colchicine were both time- and  dose- 
dependent. These and other data suggested that the generation of cyclic AMP is 
normally restricted by an intact system of cytoplasmic microtubules.  If so, then 
the  same  time  and  dose  dependencies might  apply to  other colchicine-induced 
changes in leukocyte function. 
We  have  now  assayed  the  distribution  of concanavalin  A  (Con  A)-receptor 
complexes  on  the  leukocyte  membrane,  taking  into  account  that  leukocytes 
competent  to  assemble  microtubules  show  a  uniform  distribution  of  surface- 
bound Con  A  whereas microtubule-deficient cells accumulate Con  A  in surface 
caps.  We have found that the effect of colchicine on capping is also both time- 
and dose-dependent, and that the dose-response relationships conform to those 
required to increase cyclic AMP levels. These findings provide further evidence 
that both colchicine-induced Con-A capping and colchicine-induced cyclic AMP 
generation  depend  upon  the  relaxation  of  constraints  normally  imposed  by 
cytoplasmic microtubules upon the plasma  membrane, which limit, respectively, 
lateral  mobility  of the  lectin-receptor complexes,  and  expression  of hormone- 
sensitive adenylate cyclase. 
Moreover, colchicine-induced Con-A cap formation is not affected even by very 
large changes in leukocyte cyclic AMP levels. Thus, elevated cyclic AMP levels 
do not appear to promote the dissolution of microtubules; rather, the dissolution 
of microtubules permits the generation of increased amounts of cyclic AMP. 
KEY  WORDS  human  leukocytes  microtubule 
assembly (disassembly)  3'.5'-cyclic  adenosine 
monophosphate (cyclic  AMP)  concanavalin  A 
(Con A)-receptor complex  Con-A 
capping  colchicine  -  isoproterenol 
The  existence  in  polymorphonuclear leukocytes 
(PMN)  of  colchicine-sensitive  microtubules  (6) 
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during phagocytosis (7, 8) was first established a 
decade  ago.  Other  colchicine-sensitive (presum- 
ably microtubule-dependent)  PMN functions have 
since  been  described.  For  example,  colchicine 
inhibits the  segregative  movement of membrane 
proteins (16, 10) and lipids (2) during phagocyto- 
sis and enhances the movement of concanavalin A 
(Con A)-receptor complexes into caps (11). These 
studies  suggest  that  microtubules  may  interact 
with the  plasma membrane to  restrain or direct 
the topographical distribution of membrane com- 
ponents. 
Despite increasing insight into likely functions 
of microtubules, the mechanism(s) of microtubule 
assembly and disassembly in PMN has remained 
obscure.  Weissman, Ignarro, and others  (18,  5, 
17) consider that microtubule assembly-disassem- 
bly is modulated by cyclic nucleotides. Thus. like 
colchicine, both cyclic AMP and compounds that 
increase its intracellular level diminish the release 
of lysosomal enzymes from leukocytes after vari- 
ous  stimuli.  In  contrast,  both  cyclic  GMP  and 
agents that increase its intracellular concentration 
augment enzyme release in the same systems. In 
the case of cyclic GMP. the nucleotide appears to 
promote  microtubule  polymerization,  as  deter- 
mined by counts of microtubule profiles in thin 
sections  of  fixed,  stimulated  cells  (17).  The 
opposite assumption-that cyclic AMP promotes 
the dissolution of microtubules-is more difficult 
to  examine  directly,  because  thin  sections  of 
resting PMN exhibit rather few microtubule pro- 
files to begin with. This report will  suggest that 
elevated cyclic AMP levels in human leukocytes 
do not promote the dissolution of microtubules. 
There is,  however, a  close relationship, but it 
works  the  other  way  around:  we  have  recently 
shown that the increase in human leukocyte cyclic 
AMP  levels  seen  in  response  to  a  variety  of 
substances is  markedly  potentiated  by  pretreat- 
ment  of the  cells  with colchicine or  with other 
agents that affect microtubule assembly (14). The 
effects  of colchicine were  both  time- and  dose- 
dependent; they could be seen within 1 min after 
addition of colchicine or at concentrations as low 
as  10  -8 M. Under appropriate conditions, leuko- 
cyte  cyclic  AMP levels increased more than 40- 
fold over levels in untreated cells. 
Those results suggested that the  generation of 
cyclic  AMP  is  normally restricted  by  an  intact 
microtubule system (14). If so, then the same time 
and dose dependencies might apply to other col- 
chicine-induced  changes in PMN function. On the 
other hand, if the elevation of cyclic AMP levels 
induces microtubule disassembly, then  microtu- 
bule-dependent  functions  should  be  impaired 
more rapidly than normal, or  at  lower doses of 
colchicine, in cells exposed both to colchicine and 
to substances that enhance the generation of cyclic 
AMP. In the present study, we have assayed the 
distribution of Con A-receptor complexes on the 
PMN  membrane. As  described  before  (11-13), 
cells competent to assemble microtubules show a 
uniform  distribution  of  surface-bound  Con  A 
whereas  microtubule-deficient cells  accumulate 
Con A  in surface caps.  We have found that  (a) 
the  effect  of colchicine on capping is  also  both 
time-  and  dose-dependent,  (b)  the  colchicine 
doses required to induce capping conform to those 
required to increase leukocyte cyclic AMP levels, 
but (c)  Con-A cap formation is  not affected  by 
very large changes in cyclic AMP levels. 
MATERIALS  AND  METHODS 
Human ieukocytes were obtained from freshly drawn, 
heparinized blood from healthy adult donors, either in 
buffy coats (for capping) or after dextran sedimentation 
(for cyclic AMP levels), as  described previously (11, 
14), and suspended in a modified Krebs-Ringer phos- 
phate  buffer,  pH  7.4  (7).  The  leukocyte population 
consisted of -70-80%  neutrophils and  20-30%  lym- 
phocytes with 1-4% monocytes and eosinophils. Plate- 
lets were rare. For capping experiments, 0.5 ml of the 
leukocyte suspensions (-0.5  x  106  cells) were incu- 
bated  for  5  rain at  37"C with 14  /~g/mi fluorescein 
isothiocyanate-conjugated Con  A  (FITC-Con A) pre- 
pared as described previously (11). The cells were then 
fixed in an  equal  volume of  4%  paraformaldehyde, 
resuspended in buffer, and examined by combined phase 
fluorescence microscopy  with a Zeiss fluorescence  micro- 
scope.  At  least 100  cells were counted  under  each 
experimental condition. Capped  cells showed intense, 
polarized fluorescence. Cells without caps showed either 
diffuse membrane fluorescence or additional fluorescent 
patches, the latter indicating internalization of Con A 
(11). Patching occurred in only -10% of cells and was 
not  influenced consistently by the  various drugs em- 
ployed. For cyclic AMP determinations, 0.2-ml aliquots 
of the  leukocyte suspensions (-5  ￿  10  ~ cells), after 
incubations as described in the  text, were placed in a 
boiling water bath for 5 rain. After freezing, thawing, 
and the removal of particulate matter (14), cyclic AMP 
was determined in triplicate by an isotope dilution assay 
(4). For the effects of Con A on cyclic AMP levels, the 
same preparation of FITC-Con A used in the capping 
assay was incubated with leukocytes for an additional 5 
min before boiling. 
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The  effect of colchicine on Con-A cap formation 
is  illustrated  in  Fig.  1 a.  With  the  usual  30-min 
preincubation  period,  colchicine  has  a  maximal 
effect  on  Con-A  cap  formation  at  1  x  10  -~  M, 
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FIGURE  1 
and no effect at 1  ￿  10  -r M  (11). However, with 
variation in the time of preincubation, a  series of 
dose-response curves were  generated.  Thus,  col- 
chicineatl  x  10  -~M,5  x  10  -7M,2  ￿  10  -TM, 
and  1  x  10  -7  M  produced  Con-A  capping  that 
was  at  least  half-maximal  after  preincubation 
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Preineubetion  with  Colchicine  (rain) 
Time and dose dependencies of the effects of coichicine on Con-A cap formation in human 
leukoeytes. (a) Cells were preincubated at 37~  with the concentrations of eolchicine indicated; the means 
of percent capping in three experiments are shown. In one of those experiments, 1 mM IBMX ("X") was 
added to separate aliquots for an additional 2 min; in another, both IBMX and 2  /zM d,l-isoproterenol 
("X +  I") were added. Then, Con-A cap formation was determined as described in the text. Although the 
data displayed here are for PMN, lymphocytes and monocytes behaved in a qualitatively similar fashion. 
(b) The dose-response relationships from (a) are compared to those seen in the generation of cyclic AMP 
(dotted lines, replotted from reference 14). The design of the latter experiment is like that for Con-A cap 
formation except that after the 2-min incubation, which included both IBMX and isoproterenol, cyclic 
AMP levels were determined as in the text. 
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maximal after 30, 60, 120, and 120 min, respec- 
tively.  Furthermore,  the  data  in  Fig.  la  show 
that, after preincubation with colchicine, incuba- 
tion for  an  additional 2  min with  1  mM  of the 
phosphodiesterase  inhibitor,  isobutylmethylxan- 
thine  (IBMX.  -X").  or  with  IBMX  +  2  /~M 
isoproterenol  ("X  +  I")  had  no  effect  on  the 
capping  response  to  Con  A.  Lymphocytes  and 
monocytes  in  the  mixed  leukocyte  suspensions 
showed  surface  behavior qualitatively similar to 
that measured for PMN. 
Unlike  the  effects  on  Con-A cap  formation, 
preincubation with colchicine alone has no consist- 
ent effect  on leukocyte cyclic  AMP levels (14). 
However, when a  30-min preincubation was fol- 
lowed by incubation for an additional 2 min with 
1 mM IBMX, maximally effective concentrations 
of colchicine caused a more than twofold increase 
in  cyclic  AMP  levels.  Moreover,  when  2  p.M 
isoproterenol  or  10  p.M  prostaglandin  E~  was 
added with the  IBMX, the colchicine effect was 
markedly potentiated. As noted earlier, the effect 
of colchicine on the generation of cyclic AMP is 
also both time- and dose-dependent. In Fig.  lb, 
the dose-response curves are seen to conform to 
those for Con-A cap formation. Mononuclear  cells 
isolated from  Hypaque  (Winthrop Laboratories, 
New  York)-Ficoll  (Pharmacia  Fine  Chemicals 
Inc., New Market, N. J.) gradients showed similar 
increases  in  cyclic  AMP  qualitatively  to  those 
reported here for predominantly PMN. 
The addition of Con A itself did not reverse the 
accumulation of cyclic AMP induced by any of the 
experimental conditions employed  (Table  I). 
DISCUSSION 
The colchicine effect on Con-A cap formation is 
both  time-  and  dose-dependent, and  is  not  af- 
fected  by  the  addition of IBMX,  alone or with 
isoproterenol (Fig. 1 a). The colchicine effect on 
cyclic  AMP  levels  has  similar  time  and  dose 
dependency (Fig.  lb), but requires the addition 
of IBMX and is markedly potentiated by isopro- 
terenol  (14).  Thus, the  results indicate that  the 
disassembly of microtubules which precedes col- 
chicine-induced Con-A capping is not influenced 
by  large  fluctuations in  cyclic  AMP  levels.  To 
make this point unequivocally, it is still necessary 
to show that treatment with Con A itself does not 
drive  elevated  cyclic  AMP  levels  back  down. 
From the  data shown in Table I, it is clear that 
Con A  did not substantially decrease cyclic AMP 
TABLE I 
The Failure of Con A  to Decrease Cyclic AMP 
Levels in Human Leukocytes 
Cyclic AMP, pmol/10  ~  cells 
Additions  Control  Con A 
None  0.27 ___ 0.04  0.37 •  0.02 
Colchicine  0.48 •  0.02  0.37 •  0.03 
IBMX  1.07 +-- 0.03  0.97 -+ 0.04 
Colchicine + IBMX  3.19 •  0.09  2.96 •  0.09 
IBMX  +  d,l-isopro-  3.39 •  0.18  4.26 -  0.08 
terenol 
Colchicine +  IBMX  16.20  •  0.40  17.30  -  0.40 
+ isoproterenol 
Cells were preincubated  for  30  min  at  37~  in  the 
absence or presence of 10 ~M colchicine. The incuba- 
tion was continued for 2 rain without or with 1 mM 
IBMX, or 1 mM IBMX + 2 p.M d,l-isoproterenol, and 
for an additional 5 min without or with 14 p.g/ml Con 
A. Cyclic  AMP was then determined as described in the 
text. 
levels either in control cells or in cells treated with 
colchicine, IBMX,  or  IBMX  and  isoproterenol. 
We propose, therefore, that increased cyclic AMP 
does not induce Con-A capping. Rather, microtu- 
bule disassembly leads simultaneously  to increased 
cyclic AMP generation and to surface cap forma- 
tion. 
The molecular basis of colchicine-induced Con- 
A  capping and of colchicine-induced cyclic AMP 
generation may in fact be similar, When colchicine 
causes the disruption of microtubules, constraints 
on  the  lateral mobility of Con  A-receptor com- 
plexes  are  thought  to  be  relaxed,  enabling the 
complexes to migrate from homogeneous surface 
distribution into surface caps from which they will 
eventually be internalized (15,  1).  The effect  of 
colchicine on cyclic AMP levels may depend on a 
similar relaxation of constraints normally imposed 
by cytoplasmic microtubules on the expression of 
hormone-sensitive  adenylate cyclase in the plasma 
membrane (14). Consistent with this view are the 
observations that  (a) a phosphodiesterase inhibi- 
tor  (IBMX)  is  required  to  see  the  effects  of 
colchicine,  suggesting  increased  production  of 
cyclic AMP rather than decreased hydrolysis, (b) 
potentiation of the colchicine effect  is seen with 
agents that  act  through three  separate  hormone 
receptors  in  membranes-isoproterenol, prosta- 
glandin El, and histamine,  t (c) similar effects are 
seen with other agents that interfere with micro- 
1 The histamine data are unpublished. 
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phyilotoxin, oncodazole-but not with lumicolchi- 
cine, which does not interfere, and (d) the colchi- 
cine effects disappear  when  the cells are broken, 
even though the hormone  effects persist  in mem- 
brane preparations  (14). 
Ordering the relationship between microtubule 
disassembly  and cyclic AMP generation  in leuko- 
cytes  is  helpful  in  defining the  specific pathways 
by  which  these  discrete  but  overlapping  events 
affect  cell  structure  and  function.  For  example, 
the  leukocytes  in  patients  with  the  Chediak-Hi- 
gashi  syndrome  have  various  functional  defects, 
deficient  microtubule  assembly  (associated  with 
spontaneous Con-A cap formation), and markedly 
elevated cyclic AMP levels, all of which approach 
normal  with  appropriate  therapy  (3,  12).  The 
present  results  indicate  that  the  cyclic AMP ele- 
vation in these genetically abnormal  cells may be 
a  consequence  and  not  a  cause  of the  defect  in 
microtubule assembly. 
More generally, our findings suggest that  some 
colchicine-sensitive cellular functions now thought 
to be microtubule-dependent  may in fact be cyclic 
AMP-dependent  in  PMN  and  in  other cells.  For 
example the therapeutic  anti-inflammatory action 
of  colchicine  in  acute  gouty  arthritis  and  other 
disorders  may be mediated  in  part  through  inter- 
ference  with  microtubule  assembly  and  function 
(9)  and  in  part  through  cyclic  AMP  generated 
when microtubules disassemble. If effects of cyclic 
AMP occur, they are most likely submaximal and 
may be potentiated by the addition of other agents 
that  raise  cyclic AMP levels. The  demonstration 
in appropriate cell systems of functional synergism 
between these two classes of well-established ther- 
apeutic  agents-those  that  affect microtubule  as- 
sembly and those that stimulate adenylate cyclase 
activity-could  be  applied  to  a  wide  variety  of 
therapeutic  problems, of which the most immedi- 
ately  apparent  are  in  inflammation,  allergy  and 
hypersensitivity, and neoplasia. 
Dr. Rudolph was the recipient of a National Institutes of 
Health postdoctoral fellowship and  carried out part  of 
this work in the laboratory of Dr. Paul Greengard. The 
work was  supported  in  part  by grants  from the  U.  S. 
Public  Health  Service (AM  10493,  AM  19742,  AM 
07107,  ES  01106,  CA  18564,  MH  17387,  and  NS 
08440), the Kroc Foundation, the Arthritis Foundation, 
and the American Cancer Society. 
Received  for  publication  9  November  1977,  and  in 
revised form 3 February 1978. 
REFERENCES 
1.  ALRERTI~I, D.  F.,  R.  D.  BERLITZ, and  J.  M. 
OLWEa. 1977.  The mechanism of concanavalin A 
cap formation in leukocytes. J.  Cell Sci.  26"57-75. 
2.  BERLIN, R. D., and J.  P. FERA. 1977.  Changes in 
membrane microviscosity  associated with phagocy- 
tosis.  Effects of colchicine. Proc.  Natl.  Acad.  Sci. 
U. S. A. 74"1072-1076. 
3.  BOXER, L.  A.,  A. M.  WATANABE, M.  RISTER, H. 
R.  BESCH, JR.,  J.  ALLEN, and  R.  L.  BAEHNER. 
1976.  Correction of leukocyte function in Chediak- 
Higashi syndrome by ascorbate.  N.  Engl.  J.  Med. 
295:1041-1045. 
4.  BROWN, B. L., J. D. M. ALBANO, R. P. EKINS, A. 
M.  SGHERZl, and  W.  TAMPION. 1971.  A  simple 
and sensitive  saturation assay  method for the mea- 
surement of adenosine 3' ,5'-cyclic monophosphate. 
Biochem.  J. 121:561-562. 
5.  IGNARRO. L.  J.,  and  W.  J.  GEORGE. 1974.  Hor- 
monal  control  of lysosomal  enzyme  release  from 
human  neutrophils:  elevation of cyclic  nucleotide 
levels by  autonomic  neurohormones.  Proc.  Natl. 
Acad. Sci.  U. S. A. 71:2027-2031. 
6.  MALAWISTA, S.  E.,  and  K.  G.  BENSCH. 1967. 
Human polymorphonuclear leukocytes: demonstra- 
tion of microtubules and effect of colchicine. Science 
(Wash. D. C.). 156:521-522. 
7.  MALAWmTA, S.  E.,  and  P.  T.  BODEL. 1967.  The 
dissociation  by colchicine  of phagocytosis  from in- 
creased oxygen consumption in human leukocytes. 
J. Clin. Invest.  46:786-796. 
8.  MALAWISTA, S.  E.  1975.  Microtubules  and  the 
mobilization of lysosomes in phagocytizing human 
leukocytes. Ann. N. Y. Acad. Sci.  253:738-749. 
9.  MALAWISTA,  S.  E.  1975.  The  action of colchicine 
in  acute gouty arthritis. Arthritis  Rheum.  18:835- 
846. 
10.  OLIVER, J.  M.,  T.  E.  UKENA, and  R.  D. BERLIN. 
1974.  Effects  of  phagocytosis  and  colchicine  on 
distribution of lectin-binding sites  on cell surfaces. 
Proc. Natl. Acad. Sci.  U. S. A. 71:394-398. 
11.  OLIVER,  J. M. 1976.  Concanavalin A cap formation 
on  human  polymorphonuclear leukocytes induced 
by R17934,  a  new antitumor  drug  that  interferes 
with  microtubule  assembly.  J.  Reticuloendothel. 
Soc.  19:389-395. 
12.  OLIVER,  J. M. 1976.  Impaired microtubule function 
correctable by cyclic GMP and cholinergic agonists 
in the Chediak-Higashi syndrome. Am. J.  Pathol. 
85:395-418. 
13.  OHVER,  J.  M.,  D.  F.  ALBERaaNI, and  R.  D. 
BERLIN.  1976.  Effects  of  glutathione-oxidizing 
agents on  microtubule  assembly  and  microtubule- 
dependent surface properties of human neutrophils. 
J. Cell Biol.  71:921-932. 
RUDOLPH. S. A., P. GREENGARD,  and S. E. MALA- 
WISTA. 1977.  Effects of colchicine on cyclic AMP 
levels in human leukocytes. Proc.  Natl.  Acad.  Sci. 
14. 
MALAWISTA, OLIVER, AND  RUDOLPH  Microtubules  and Cyclic AMP in Human Leukocytes  885 U. S. A. 74:3404-3408. 
15.  SCHREINER,  G.  F.,  and  E.  L.  UNANUE. 1976. 
Membrane and cytoplasmic changes in B lympho- 
cytes  induced  by  ligand-surface  immunoglobulin 
interaction. Adv. lmmunol. 24:37-165. 
16.  UKENA, T. E., and R. D. BERLIN. 1972.  Effect of 
colchicine and vinblastine on the topographical sep- 
aration  of  membrane  functions.  J.  Exp.  Med. 
136:1-7. 
17.  WEISSMANN, G., I. GOLDSTEIN, S.  HOFFSTEIN, and 
PI-K.  TSUNG. 1975.  Reciprocal effects of cAMP 
and  cGMP  on  microtubule-dependent release  of 
lysosomal  enzymes.  Ann.  N.  Y.  Acad.  Sci. 
254:750-762. 
18.  ZURIER, R.  B.,  G.  WEISSMANN, S.  HOFFSTErN, S. 
KAMMERMAN, and  H.  H.  TAI. 1974.  Mechanisms 
of lysosomal enzyme  release from  human  leuko- 
cytes. J. Clin.  Invest. 53:297-309. 
886  TrIE JOURNAL OF  CELL BIOLOGY ￿9 VOLUME 77,  1978 